FDA panel supports edoxaban for stroke prevention

Angela Marshall | | Cardiovascular Business | Vascular & Endovascular

An FDA advisory panel voted 9-1 in favor of approval of the anticoagulant edoxaban to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

The Cardiovascular and Renal Drugs Advisory Committee reviewed the safety and efficacy results from the ENGAGE-AF-TIMI 48 trial. Findings pointed to a reduced rate of stroke and systemic embolism in nonvalvular atrial fibrillation patients and showed edoxaban as noninferior to warfarin in the prevention of stroke or systemic embolism using both high and low dosage (60 mg and 30 mg).

While the committee approved edoxaban (Savaysa, Daiichi Sanko) for use, voting was divided on whether or not a 60 mg dose should be administered for patients with normal renal function due to some increased risks for bleeding seen in a subanalysis. FDA representative Ellis Unger, MD, said of the dosage issue, “The people prescribing this are pretty sophisticated physicians. (Adjusting doses) is doable.”

Edoxaban is a Factor Xa inhibitor. The FDA already gave a green light to two other Factor Xa inhibitors, rivaroxaban (Xarelto, Janssen Pharmaceuticals/Bayer HealthCare) and apixaban (Eliquis, Bristol-Myers Squibb/Pfizer), for this indication. The thrombin-inhibitor dabigatran (Pradaxa, Boehringer Ingelheim) also is marketed in the U.S.

The FDA often but not always follows the recommendations of its advisory committees.

Angela Marshall

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."